Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at UTHealth. 

Using human-induced pluripotent stem cells engineered from a single family’s blood samples, a gene signaling pathway linked to a higher risk for developing schizophrenia was discovered by scientists at UTHealth. The research was published in a recent issue of Neuropsychopharmacology.

Unraveling the links among obesity, aging, telomere lengths and metabolic diseases is the subject of the study published today in Nature Metabolism by a collaborative research team at The University of Texas Health Science Center at Houston (UTHealth).

A pattern in how the brain breaks down tryptophan, a common amino acid consumed through food, was discovered by researchers at UTHealth. The finding, which could help physicians more accurately diagnose and treat several major mental health disorders, was recently published in Molecular Psychiatry.

Researchers are investigating whether a human umbilical cord patch placed on the spina bifida defect could improve healing after minimally invasive fetoscopic surgery in a clinical trial at The University of Texas Health Science Center at Houston (UTHealth).

When medically complex children are hospitalized, linking hospitalists to their regular outpatient providers through an inpatient consultation service were more likely to improve outcomes, according to researchers at The University of Texas Health Science Center at Houston (UTHealth).

The uniquely human ability to read is the cornerstone of modern civilization, yet very little is understood about the effortless ability to derive meaning from written words. Scientists at UTHealth have now identified a crucial region in the temporal lobe, know as the mid-fusiform cortex, which appears to act as the brain’s visual dictionary.

When Rodolfo Sandoval was told he would need to undergo open surgery to repair his thoracic and abdominal aortic aneurysm, he hesitated. At 73 years old, he was worried about the recovery process for a major, invasive procedure. Then COVID-19 arrived and he made the decision that he would only consider the surgery if it became a life or death situation.

Researchers are assessing whether magnetic seizure therapy (MST) can help relieve treatment-resistant depression in bipolar patients in a clinical trial led by UTHealth. 

Neurologists are researching whether a novel immunomodulatory treatment, OP-101, can dampen lung and brain injury in hospitalized COVID-19 patients through a clinical trial at The University of Texas Health Science Center at Houston (UTHealth).

The very heart of inpatient care for psychiatric patients is socialization, group therapy, shared meals, and a standard two people per room. Then COVID-19 hit with the accompanying public health warnings to isolate, socially distance, and wear masks. UTHealth HCPC had to walk the line between the two.

A Phase III clinical trial to assess if a potential vaccine is effective at preventing symptomatic COVID-19 is now open for enrollment by The University of Texas Health Science Center at Houston (UTHealth) in collaboration with Memorial Hermann-Texas Medical Center.

A high-tech imaging study to understand how brain connectivity patterns change after deep brain stimulation in patients suffering from essential tremor has been launched at The University of Texas Health Science Center at Houston (UTHealth).

To better understand the molecular basis of Down syndrome, a genetic disease that affects 1 in 750 infants born in the U.S., researchers at The University of Texas Health Science Center at Houston (UTHealth) have received a $3.1 million grant from the National Institutes of Health (NIH).

Pregnant Hispanic patients were nearly twice as likely to be diagnosed with COVID-19 than other racial-ethnic groups and most were asymptomatic, according to research by The University of Texas Health Science Center at Houston (UTHealth).

Studying how neurons work together in order to better understand neurological disorders such as Alzheimer’s disease and autism spectrum disorders, researchers led by John Byrne, PhD, at The University of Texas Health Science Center at Houston (UTHealth) have been awarded more than $3 million from the National Institutes of Health BRAIN Initiative.

A $53.6 million grant from the National Institutes of Health will aid brain scientists, including a researcher from The University of Texas Health Science Center at Houston (UTHealth), in studying the role of incidental white matter lesions, or WMLs, in dementia among diverse people with cognitive complaints.

Results of a first-of-its-kind clinical trial shed light on when antibiotics instead of surgery might be the better choice for treating appendicitis in some patients, according to researchers with The University of Texas Health Science Center at Houston (UTHealth), who led the Houston trial sites.

To help reduce COVID-19-related health disparities in vulnerable populations in Texas, a multi-institutional team of researchers led by The University of Texas Health Science Center at Houston (UTHealth) will identify disease hotspots and testing deserts in three racially diverse areas, and then develop and evaluate intervention strategies to increase COVID-19 testing.

Bringing together expertise and access to the best clinical care, research trials, discovery science, and public health knowledge, The University of Texas Health Science Center at Houston (UTHealth) has established the UTHealth COVID-19 Center of Excellence.

Researchers at The University of Texas Health Science Center at Houston (UTHealth) are investigating the efficacy and safety of an intranasal treatment for adults with chronic sinusitis with or without nasal polyps.

In the first of its kind for the tiniest stroke survivors, researchers at The University of Texas Health Science Center at Houston (UTHealth) will lead a stroke rehabilitation clinical trial in the state of Texas through a multi-institutional NIH StrokeNet initiative.

For months, experts have warned against the use of anti-inflammatory medications, such as ibuprofen, to treat COVID-19 symptoms. But could the timing of when this drug is taken play a role in its effectiveness?